<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052675</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/07/10-C</org_study_id>
    <nct_id>NCT01052675</nct_id>
  </id_info>
  <brief_title>Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation</brief_title>
  <official_title>Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, the Afssaps is the body in charge of the evaluation of pharmacodependance. In&#xD;
      order to fulfil its mission, the Afssaps has created a network of 11 Centres for Evaluation&#xD;
      and Information on Pharmacodependance (CEIP), coordinated by the Drugs and Psychotropics&#xD;
      Unit. Pharmacodependence notifications issued by professionals are collected by each Centre&#xD;
      which evaluates them. Nantes' CEIP created an original tool to harmonize case reporting and&#xD;
      make it possible to homogeneously evaluate the seriousness of pharmacodependence cases as&#xD;
      each CEIP had his own way of analysing his cases. The aim of this study is to assess this&#xD;
      tool.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2008</start_date>
  <completion_date type="Actual">September 15, 2013</completion_date>
  <primary_completion_date type="Actual">June 14, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometrics properties Evaluation of the new questionnaire centered on addiction to medicine .</measure>
    <time_frame>At the beginning of the study</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3180</enrollment>
  <condition>Drug Abuse</condition>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Pharmacodependance cases</arm_group_label>
    <description>Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pharmacodependent patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  case report from one of the French CEIP for drug and substance problematic use, abuse&#xD;
             or dependence except alcohol and tobacco.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolliet Pascale, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nantes's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antipoison - Centre de Pharmacovigilance</name>
      <address>
        <city>Lyon</city>
        <zip>69424</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Salvator</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Fernand Widal</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculté de médecine</name>
      <address>
        <city>Toulouse</city>
        <zip>31073</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug and substance problematic use, abuse or dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

